Valentina Cenacchi
Parma, 43122, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD.
Journal: Journal of medicinal chemistry
Published: August 10, 2023
ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 28, 2023
Development and validation of a bioanalytical method for the quantification of CHF6550 and its metabolite (CHF6671) in rat plasma and lung homogenate using LC-MS/MS.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: December 23, 2022
Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease.
Journal: Journal of medicinal chemistry
Published: June 18, 2021
Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
Journal: Journal of medicinal chemistry
Published: May 10, 2018
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Journal: Journal of medicinal chemistry
Published: December 05, 2017
Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology.
Journal: Journal of aerosol medicine and pulmonary drug delivery
Published: August 03, 2017
Role of efflux transporters in the absorption, distribution and elimination in rodents of a novel PDE4 inhibitor, CHF6001.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: August 03, 2017
Synthesis of 14 C- and 2 H-labelled CHF6001: A new potent PDE4 inhibitor.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: June 14, 2017
In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: March 04, 2015
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
Journal: The Journal of pharmacology and experimental therapeutics
Published: January 11, 2015
Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration.
Journal: Steroids
Published: June 04, 2014
Last Updated: 09/26/2026